JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Twist Bioscience (NASDAQ:TWST) Corp’s stock has reached a significant milestone, hitting a 52-week low of 27.12 USD. This marks a notable decline for the company, which has seen its stock price decrease by 38.23% over the past year. Despite the downturn, InvestingPro data shows the company maintains strong liquidity with a current ratio of 3.9 and holds more cash than debt on its balance sheet. The biotechnology firm’s stock performance reflects broader challenges in the sector, as investors weigh the company’s financial health and future growth potential. With a beta of 2.37 and revenue growth of 22.72% in the last twelve months, the stock’s volatility remains high. The drop to this 52-week low underscores the market pressures faced by Twist Bioscience, with technical indicators suggesting oversold conditions. For deeper insights into Twist Bioscience’s financial health and additional ProTips, visit InvestingPro, where you’ll find comprehensive analysis and expert research reports.
In other recent news, Twist Bioscience reported a notable 18% increase in revenue for Q3 2025, reaching $96.1 million. Despite this growth, the company experienced an adjusted EBITDA loss of $8 million, though this marks an improvement compared to the prior fiscal year. In addition to financial updates, Twist Bioscience announced the appointment of Trynka Shineman Blake to its board of directors, where she will also serve on the audit committee. Blake brings extensive experience from her previous role as CEO of Vistaprint, where she significantly grew the business.
Analyst activity around Twist Bioscience has been active, with JPMorgan lowering its price target from $33 to $25, maintaining an Underweight rating. TD Cowen also adjusted its price target down to $36 from $58, but continues to hold a Buy rating, citing changes in revenue guidance. Evercore ISI followed suit by reducing its price target to $46 from $50, while maintaining an Outperform rating, highlighting strong performance in the next-generation sequencing segment. These developments reflect the evolving outlook for Twist Bioscience amid shifting market dynamics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.